UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 376

Sortiert nach

Inflammatory and Cholesterol Risk in the FOURIER Trial

Circulation (New York, N.Y.), 2018-07, Vol.138 (2), p.131-140

2018

Volltextzugriff (PDF)

Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials

The lancet oncology, 2011, Vol.12 (1), p.65-82

2011

Volltextzugriff (PDF)

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

The Lancet (British edition), 2005-09, Vol.366 (9489), p.907-913

2005

Volltextzugriff (PDF)

Clinical benefits of evolocumab appear less than hoped – Authors' reply

The Lancet (British edition), 2018-03, Vol.391 (10124), p.934-935

2018

Volltextzugriff (PDF)

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial

Circulation (New York, N.Y.), 2019-03, Vol.139 (12), p.1483-1492

2019

Volltextzugriff (PDF)

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Stroke (1970), 2020-05, Vol.51 (5), p.1546-1554

2020

Volltextzugriff (PDF)

Evaluation of C-Reactive Protein Before and On-Treatment as a Predictor of Benefit of Atorvastatin

Journal of the American College of Cardiology, 2013-08, Vol.62 (8), p.717-729

2013

Volltextzugriff (PDF)

The importance of a valid assessment of salt intake in individuals and populations. A scientific statement of the British and Irish Hypertension Society

Journal of human hypertension, 2019-05, Vol.33 (5), p.345-348

2019

Volltextzugriff (PDF)

Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL

Circulation (New York, N.Y.), 2021-11, Vol.144 (21), p.1732-1734

2021

Volltextzugriff (PDF)

Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial

European heart journal, 2021-12, Vol.42 (47), p.4821-4829

2021

Volltextzugriff (PDF)

Hypertension management 2011: optimal combination therapy

European heart journal, 2011-10, Vol.32 (20), p.2499-2506

2011

Volltextzugriff (PDF)

Reply to Chiolero: Salt intake monitoring at a population level

Journal of human hypertension, 2020-09, Vol.34 (9), p.666-667

2020

Volltextzugriff (PDF)

Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial

European heart journal, 2024-04, Vol.45 (13), p.1159-1169

2024

Volltextzugriff (PDF)

Correction: The importance of a valid assessment of salt intake in individuals and populations. A scientific statement of the British and Irish Hypertension Society

Journal of human hypertension, 2020-04, Vol.34 (4), p.338-338

2020

Volltextzugriff (PDF)

The Anglo-Scandinavian Cardiac Outcomes Trial: Implications and Further Outcomes

Hypertension (Dallas, Tex. 1979), 2012-08, Vol.60 (2), p.248-259

Sever, Peter S

2012

Volltextzugriff (PDF)

Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy

Circulation (New York, N.Y.), 2021-07, Vol.144 (3), p.249-251

2021

Volltextzugriff (PDF)

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

BMJ (Online), 2004-03, Vol.328 (7440), p.634-640

International edition, 2004

Volltextzugriff (PDF)

Sodium and Health: Old Myths and a Controversy Based on Denial

Current nutrition reports, 2022-06, Vol.11 (2), p.172-184

2022

Volltextzugriff (PDF)

Aspirin and primary prevention. BHS reaffirms its guidance

BMJ (Online), 2010-03, Vol.340, p.c1183

Sever, Peter S

2010

Volltextzugriff (PDF)

Differential Effects of Antihypertensive Treatment on Left Ventricular Diastolic Function

Journal of the American College of Cardiology, 2010-04, Vol.55 (17), p.1875-1881

2010

Volltextzugriff (PDF)

Managing cardiovascular and renal risk: the potential of direct renin inhibition

Journal of the renin-angiotensin-aldosterone system, 2009-06, Vol.10 (2), p.65-76

2009

Volltextzugriff (PDF)

Calcium channel regulation in vascular smooth muscle cells: Synergistic effects of statins and calcium channel blockers

International journal of cardiology, 2010-02, Vol.139 (1), p.2-6

2010

Volltextzugriff (PDF)

Blood pressure reduction is not the only determinant of outcome

Circulation (New York, N.Y.), 2006-06, Vol.113 (23), p.2754-2774

2006

Volltextzugriff (PDF)

Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA)

The American journal of cardiology, 2005-09, Vol.96 (5), p.39-44

2005

Volltextzugriff (PDF)

1 – 25 von 376

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(358)
Mit Volltextzugriff
(331)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(167)
Life Sciences & Biomedicine
(148)
Humans
(120)
Cardiovascular System & Cardiology
(59)
Hypertension
(51)
Biological And Medical Sciences
(48)
Medical Sciences
(44)
Peripheral Vascular Disease
(41)
Hypertension - Drug Therapy
(37)
Blood Pressure
(31)
General & Internal Medicine
(31)
Medicine, General & Internal
(31)
Antihypertensive Agents - Therapeutic Use
(25)
Animals
(23)
Cardiac & Cardiovascular Systems
(23)
Cardiovascular Disease
(23)
Cardiology. Vascular System
(21)
Pharmacology. Drug Treatments
(20)
Adult
(17)
Risk Factors
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Inflammatory and Cholesterol Risk in the FOURIER Trial

Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials

Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　― A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

Clinical benefits of evolocumab appear less than hoped – Authors' reply

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Evaluation of C-Reactive Protein Before and On-Treatment as a Predictor of Benefit of Atorvastatin

The importance of a valid assessment of salt intake in individuals and populations. A scientific statement of the British and Irish Hypertension Society

Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL

Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial

Hypertension management 2011: optimal combination therapy

Reply to Chiolero: Salt intake monitoring at a population level

Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial

Correction: The importance of a valid assessment of salt intake in individuals and populations. A scientific statement of the British and Irish Hypertension Society

The Anglo-Scandinavian Cardiac Outcomes Trial: Implications and Further Outcomes

Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

Sodium and Health: Old Myths and a Controversy Based on Denial

Aspirin and primary prevention. BHS reaffirms its guidance

Differential Effects of Antihypertensive Treatment on Left Ventricular Diastolic Function

Managing cardiovascular and renal risk: the potential of direct renin inhibition

Calcium channel regulation in vascular smooth muscle cells: Synergistic effects of statins and calcium channel blockers

Blood pressure reduction is not the only determinant of outcome

Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA)

Aktive Filter

Suchergebnisse filtern